Compare Stocks → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYADNASDAQ:LUMONASDAQ:PHASNASDAQ:RGLSOTCMKTS:XYNO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsLUMOLumos Pharma$3.02+0.7%$2.83$2.41▼$4.55$24.52M0.6625,204 shs31,235 shsPHASPhaseBio Pharmaceuticals$0.00$0.07▼$4.08$3.50M2.57848,888 shsN/ARGLSRegulus Therapeutics$2.25-0.9%$2.37$1.08▼$3.79$147.29M1.592.21 million shs612,282 shsXYNOXynomic Pharmaceuticals$2.22$2.22$0.20▼$3.84N/AN/AN/AN/A5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%+3.45%LUMOLumos Pharma+0.67%-0.66%+12.27%+1.00%-11.70%PHASPhaseBio Pharmaceuticals0.00%0.00%0.00%0.00%+42.86%RGLSRegulus Therapeutics-0.88%-16.36%-16.67%+44.23%+50.00%XYNOXynomic Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/ALUMOLumos Pharma1.55 of 5 stars3.51.00.00.00.02.51.3PHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARGLSRegulus Therapeutics2.4125 of 5 stars4.42.00.00.01.91.70.0XYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad OncologyN/AN/AN/AN/ALUMOLumos Pharma3.00Buy$18.00496.03% UpsidePHASPhaseBio PharmaceuticalsN/AN/AN/AN/ARGLSRegulus Therapeutics2.80Moderate Buy$7.25222.22% UpsideXYNOXynomic PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest RGLS, CYAD, LUMO, PHAS, and XYNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/20/2024LUMOLumos PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00LUMOLumos Pharma$2.05M11.96N/AN/A$3.45 per share0.88PHASPhaseBio Pharmaceuticals$818K0.00N/AN/A($1.93) per share0.00RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/ALUMOLumos Pharma-$34.03M-$4.19N/AN/AN/A-1,659.39%-85.63%-65.30%5/15/2024 (Estimated)PHASPhaseBio Pharmaceuticals-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/ARGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%N/AXYNOXynomic PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ALatest RGLS, CYAD, LUMO, PHAS, and XYNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/A3/7/2024Q4 2023LUMOLumos Pharma-$1.18-$1.17+$0.01-$1.17$0.01 million$0.83 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/ALUMOLumos PharmaN/AN/AN/AN/AN/APHASPhaseBio PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AXYNOXynomic PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad OncologyN/AN/AN/ALUMOLumos PharmaN/A5.695.69PHASPhaseBio PharmaceuticalsN/A0.470.47RGLSRegulus TherapeuticsN/A3.313.31XYNOXynomic PharmaceuticalsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/ALUMOLumos Pharma33.99%PHASPhaseBio Pharmaceuticals49.02%RGLSRegulus Therapeutics92.38%XYNOXynomic PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%LUMOLumos Pharma25.40%PHASPhaseBio Pharmaceuticals9.90%RGLSRegulus Therapeutics4.35%XYNOXynomic Pharmaceuticals86.29%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableLUMOLumos Pharma338.12 million6.06 millionNot OptionablePHASPhaseBio Pharmaceuticals6049.86 million44.92 millionNot OptionableRGLSRegulus Therapeutics3065.46 million62.62 millionOptionableXYNOXynomic Pharmaceuticals27N/AN/ANot OptionableRGLS, CYAD, LUMO, PHAS, and XYNO HeadlinesSourceHeadlineFull-Time MBA concentration in Pharmaceutical Managementbusiness.rutgers.edu - April 28 at 6:25 PMGlioblastoma Pipeline Landscape Report 2024: Pivotal Advances in Treatment Protocols and Drug Developmentsfinance.yahoo.com - April 26 at 8:46 AMNon-Hodgkin Lymphoma Pipeline Landscape 2024: Analysis of Over 220 Potential Pharmaceuticals in Developmentfinance.yahoo.com - April 25 at 8:03 AMWatson Pharmaceuticalsforbes.com - February 21 at 10:13 PMElite Pharmaceuticals Inc.wsj.com - February 14 at 12:30 PMHDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightfinance.yahoo.com - January 8 at 3:26 PMFennec Pharmaceuticals Inc FENCmorningstar.com - November 1 at 1:58 AMStarfield:Pharmaceuticalsvideogamer.com - September 26 at 5:59 PMDelveInsight Highlights Major Advances, Transformative Therapies, and 195+ Leading Players Wheeling the Glioblastoma Clinical Trial Pipeline Landscapebenzinga.com - September 1 at 8:35 PMGlaxosmithkline Pharmaceuticalslivemint.com - July 8 at 4:16 PMCompany History - Paam Pharmaceuticalsmoneycontrol.com - May 30 at 7:13 AMGlenmark Pharmaceuticals Get USFDA Nod For Human Trial Of Advanced Cancer-Treating Drugoutlookindia.com - March 18 at 3:41 PMDelveInsight Evaluates a Robust High-grade Glioma Pipeline as 120+ Influential Pharma Players to Set Foot in the Domainfinance.yahoo.com - March 13 at 6:05 PMPharmaceutical Secondary Packaging Equipment Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028marketwatch.com - October 7 at 12:35 AMP53 Antagonist Shows Early Activity in Advanced Liposarcomamedpagetoday.com - June 8 at 9:53 PMSelinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trialascopubs.org - April 10 at 9:25 AMFollicular Lymphoma Market to Witness Expansion at a 6.85% CAGR during the Study Period [2018-2030], States DelveInsightfinance.yahoo.com - February 9 at 12:55 PMXynomic Pharmaceuticals Holdings Inc (XYNO)investing.com - January 5 at 10:07 PMFollicular Lymphoma Market Size 2021: CAGR Value, Top Manufacturers, Industry Share, Growth, Supply Demand and Forecast till 2026wboc.com - November 10 at 7:29 PMFollicular Lymphoma Drug Landscape Report 2021 - ResearchAndMarkets.comnz.finance.yahoo.com - August 7 at 7:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsSeagate Technology Warns Cloud Demand is Heating Up April 30, 2024 10:10 AMView Seagate Technology Warns Cloud Demand is Heating Up 3 Stocks Getting Boosted by AnalystsMay 6, 2024 6:05 AMView 3 Stocks Getting Boosted by AnalystsAll Headlines Company DescriptionsCelyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Lumos PharmaNASDAQ:LUMOLumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.PhaseBio PharmaceuticalsNASDAQ:PHASPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Xynomic PharmaceuticalsOTCMKTS:XYNOXynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.